Eloralintide weight loss study for adults with excess weight and type 2 diabetes
Tests eloralintide against placebo for weight loss in adults with type 2 diabetes.
Plain-language title generated from the registry record
Registry title: A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
Key facts
- Where
- Albuquerque, Aurora, Austin, Birmingham, Bridgeport, Canoga Park, Chesterfield, Columbia, Corpus Christi, Cullman, Dallas, Daytona Beach, Delray Beach, Dunwoody, Eatontown, Escondido, Fargo, Fleming Island, Fort Worth, Greenbrae, Greensboro, Hamden, Honolulu, Houston, Indianapolis, Inverness, Jacksonville, Lawrenceville, Lima, Long Beach, Long Island City, Los Alamitos, Los Angeles, Macon, Mesquite, Metairie, Miami, Monroe, Morehead City, Mt. Dora, Mt. Pleasant, New Bedford, Ogden, Pembroke Pines, Pittsburgh, Plano, Portland, San Antonio, Sandy City, Santa Clarita, Skokie, Spring Valley, Springfield, Tucson, Uniontown, Walnut Creek, Warren Township, Wilmington, and Winter Park, United StatesSee the 60 sites
- Phase
- Phase 3
Where in United States
- Albuquerque Clinical Trials, Inc.Albuquerque, United StatesTaking people
- Care Access - AuroraAurora, United StatesTaking people
- IMA Clinical Research AustinAustin, United StatesTaking people
- Birmingham Clinical ResearchBirmingham, United StatesTaking people
- New England Research Associates, LLCBridgeport, United StatesTaking people
- San Fernando Valley Health InstituteCanoga Park, United StatesTaking people
- Clinical Research ProfessionalsChesterfield, United StatesTaking people
- Centennial Medical GroupColumbia, United StatesTaking people
- Private Practice - Dr. Osvaldo A. BruscoCorpus Christi, United StatesTaking people
- Cullman Clinical TrialsCullman, United StatesTaking people
- Velocity Clinical Research, DallasDallas, United StatesTaking people
- Arrow Clinical TrialsDaytona Beach, United StatesTaking people
- Care Access - Delray BeachDelray Beach, United StatesTaking people
- Teak Research Consults - DunwoodyDunwoody, United StatesTaking people
- Hypertension & Nephrology AssociationEatontown, United StatesTaking people
- AMCR InstituteEscondido, United StatesTaking people
- Lillestol ResearchFargo, United StatesTaking people
- Fleming Island Center for Clinical ResearchFleming Island, United StatesTaking people
- Diabetes and Thyroid Center of Ft. WorthFort Worth, United StatesTaking people
- NorCal Medical Research, IncGreenbrae, United StatesTaking people
- PharmQuest Life Sciences LLCGreensboro, United StatesTaking people
- CMR of Greater New Haven, LLCHamden, United StatesTaking people
- Pacific Diabetes & Endocrine CenterHonolulu, United StatesTaking people
- Juno ResearchHouston, United StatesTaking people
- DM Clinical Research, IndianapolisIndianapolis, United StatesTaking people
- Nature Coast Clinical Research - InvernessInverness, United StatesTaking people
- Jacksonville Center for Clinical ResearchJacksonville, United StatesTaking people
- Teak Research ConsultsLawrenceville, United StatesTaking people
- Care Access - LimaLima, United StatesTaking people
- Ark Clinical ResearchLong Beach, United StatesTaking people
- NYC Research Inc.Long Island City, United StatesTaking people
- Pacific Clinical StudiesLos Alamitos, United StatesTaking people
- Inglewood ClinicalLos Angeles, United StatesTaking people
- The Jones Center Clinical ResearchMacon, United StatesTaking people
- Southern Endocrinology AssociatesMesquite, United StatesTaking people
- Clinical Trials Management, LLC d/b/a Flourish ResearchMetairie, United StatesTaking people
- Flourish Research Acquisition, LLC dba Flourish Research - North MiamiMiami, United StatesTaking people
- New Horizon Research CenterMiami, United StatesTaking people
- IMA Clinical Research Monroe-MainMonroe, United StatesTaking people
- West Clinical ResearchMorehead City, United StatesTaking people
- Adult Medicine of Lake County, Inc.Mt. Dora, United StatesTaking people
- Accellacare - Mt PleasantMt. Pleasant, United StatesTaking people
- Lucida Clinical TrialsNew Bedford, United StatesTaking people
- Ogden Clinic - Canyon ViewOgden, United StatesTaking people
- American Research Centers of FloridaPembroke Pines, United StatesTaking people
- Preferred Primary Care Physicians, Preferred Clinical Research-St. ClairPittsburgh, United StatesTaking people
- Research Your HealthPlano, United StatesTaking people
- Summit HeadlandsPortland, United StatesTaking people
- IMA Clinical Research San AntonioSan Antonio, United StatesTaking people
- Diabetes & Endocrine Treatment SpecialistsSandy City, United StatesTaking people
- Care Access - Santa ClaritaSanta Clarita, United StatesTaking people
- NorthShore University Health SystemSkokie, United StatesTaking people
- Encompass Clinical ResearchSpring Valley, United StatesTaking people
- Clinvest Headlands LLCSpringfield, United StatesTaking people
- Tucson Clinical Research InstituteTucson, United StatesTaking people
- Preferred Primary Care PhysiciansUniontown, United StatesTaking people
- Diablo Clinical Research, Inc.Walnut Creek, United StatesTaking people
- IMA Clinical Research WarrenWarren Township, United StatesTaking people
- Trial Management Associates - Wilmington - Floral ParkwayWilmington, United StatesTaking people
- Clinical Site Partners, LLC dba Flourish ResearchWinter Park, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07282600EU 2025-523658-15-00
- Record updated
- 4 November 2026
- Original description
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.Read full original descriptionShow less
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Obesity or Overweight, and Type 2 Diabetes
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo for body weight reduction in participants with overweight or obesity and type 2 diabetes. Participation in the study will last about 75 weeks.
Inclusion: Have type 2 diabetes; Are on stable treatment for type 2 diabetes for at least 90 days prior to screening; Have a BMI ≥ 27 kg/m2; Have a stable body weight (<5% body weight change) for 90 days prior to screening.
Exclusion: Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed >1 year before screening); Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening); Have had within 90 days prior to screening:; heart attack; stroke; coronary artery revascularization; unstable angina, or; hospitalization due to congestive heart failure; Have taken medications or alternative remedies intended for weight loss within 90 days of screening; Have type 1 diabetes; Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure; Have taken any of the following antihyperglycemic medications within 90 days before screening:; amylin analogs; glucagon-like peptide-1 (GLP-1) receptor agonists; glucose-dependent insulinotropic polypeptide/glucagon-like peptide-1 (GIP/GLP) receptor agonists, or; insulin.